Fig. 1 | Scientific Reports

Fig. 1

From: LINC00162 silencing enhances sorafenib sensitivity and inhibits thyroid cancer cells progression through modulation of MAPK signaling and apoptosis

Fig. 1

We selected the LINC00162 lncRNA, which is highly expressed in thyroid cancer, for our experiments. After transfecting LINC00162 siRNA using Lipofectamine, the optimum dose and transfection time were determined. Additionally, the IC50 of sorafenib alone and in combination with LINC00162 siRNA were assessed using the MTT assay. In this study, we examined the effects of LINC00162 silencing combined with sorafenib on cell cycle, apoptosis, colony formation ability, invasion, and the expression of the involved genes in the BCPAP cell line.

Back to article page